retatrutide 1mg Dosage Guide | Titration Schedule 2026 Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

Like other hair growth treatments, results are maintained only with ongoing use

Beginning with the CY 2024 performance period/2026 MIPS payment system and the EHR reporting period in CY 2024, MIPS eligible clinicians, eligible hospitals, and CAHs may spend only one performance period at the Option 1 (Pre-production and Validation) level of active engagement for the Electronic Case Reporting measure, and they must progress to the Option 2 (Validated Data Production) level of active engagement in the next performance period or EHR reporting period for which they report the measure (87 FR 70071 through 70074

they never provide compound-specific dose or cadence recommendations and never predict drug response

Kong, M.K

The SELECT trial, which followed patients on semaglutide for up to 2.5 years, found sustained weight loss without new safety concerns emerging over time